Company officials have acknowledged privately that they’ve been slow to adapt their communication strategies—which might have worked well for normal drug development—for the fevered public scrutiny that has attended the coronavirus vaccines. They have also voiced frustration that the fact the company is producing its vaccine at no profit and has gone to extraordinary lengths to ensure it can play a central role in ensuring equitable vaccination access globally and yet it has the press or politicians outside the U.K. have cut it little slack.

Instead, these company insiders say, the company seems to be subjected to even closer scrutiny. Meanwhile, Pfizer has announced it will make $15 billion from its vaccine in 2021 alone and the public seems to shrug, these company executives grumble.

But then again, no one has accused Pfizer of trying to exaggerate its clinical trial data.